53882-12-5
基本信息
Lodoxamidum
Unii-spu695od73
LODOXAMIDE USP/EP/BP
Lodoxamidum [inn-latin]
Lodoxamida [inn-spanish]
N,N'-(2-Chlor-5-cyan-3-phenylen)dioxamsaeure
2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid
2,2'-[(2-Chloro-5-cyano-1,3-phenylene)diimino]bis[2-oxoacetic acid]
Acetic acid, 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxo-
物理化学性质
| 熔点 | 212° (dec) |
| 密度 | 1.78±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMF: 3 mg/ml; DMSO: 5 mg/ml; PBS (pH 7.2): 2 mg/mL |
| 酸度系数(pKa) | 2.07±0.50(Predicted) |
| 形态 | 固体 |
| 颜色 | Off-white to pink |
| 稳定性 | 吸湿性 |
| InChI | 1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21) |
| InChIKey | RVGLGHVJXCETIO-UHFFFAOYSA-N |
| SMILES | Clc1c(cc(cc1NC(=O)C(=O)O)C#N)NC(=O)C(=O)O |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| WGK Germany | WGK 3 |
| 存储类别 | 11 - Combustible Solids |
洛度沙胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-14270R | 洛度沙胺 Lodoxamide (Standard) | 53882-12-5 | 5 mg | 1500元 |
| 2026/09/15 | HY-14270R | 洛度沙胺 Lodoxamide (Standard) | 53882-12-5 | 10 mg | 2250元 |
| 2026/09/15 | HY-14270R | 洛度沙胺 Lodoxamide (Standard) | 53882-12-5 | 25 mg | 4050元 |
常见问题列表
Lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45 Ca influx with associated histamine release in purified rat peritoneal mast cells. The chemotactic response of eosinophils to fMLP as well as to IL-5 is significant and dose-dependent inhibited by Lodoxamide. Lodoxamide is also able to strongly inhibit the release of eosinophil peroxidase after IgA-dependent activation and, to a lesser extent, the release of eosinophil cationic protein and eosinophil-derived neurotoxin.
Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep.